Long-Term Inhibition of mu Opioid Receptor Function In Vitro and In Vivo by Methocinnamox (MCAM), a Long Acting mu Opioid Receptor Antagonist

被引：0
|
作者：
Berg, Kelly [1 ]
Zamora, Joshua [1 ]
Jennings, Elaine [1 ]
Varun, Kotipalli [1 ]
Gail, Winger [1 ]
Stephen, Husbands [1 ]
Disney, Alex [1 ]
Clarke, William [1 ]
Woods, James [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2018年 / 43卷
关键词：
Opioid Overdose; Opioid Receptors; Opioid Antagonist Treatment;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
T269
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [1] Methocinnamox (MCAM) is a Selective, Long Acting Antagonist at Mu Opioid Receptor In Vitro
    Zamora, Joshua C.
    Kotipalli, Varun
    Jennings, Elaine M.
    Disney, Alex
    Husbands, Stephen
    Winger, Gail
    Clarke, William P.
    Woods, James H.
    Berg, Kelly A.
    [J]. FASEB JOURNAL, 2019, 33
  • [2] Agonist-Dependent Modulation by the Long-Acting Mu Opioid Receptor Antagonist, Methocinnamox (MCAM)
    Smith, Hudson
    Zamora, Joshua
    Chavera, Teresa
    Jennings, Elaine
    Winger, Gail
    Woods, James
    Clarke, William
    Berg, Kelly
    [J]. FASEB JOURNAL, 2020, 34
  • [3] Methocinnamox (MCAM) is an Effective Long-Term Antagonist of Peripheral Mu, but not Kappa or Delta Opioid Receptors In Vivo
    Jennings, Elaine M.
    Disney, Alex
    Husbands, Stephen
    Winger, Gail
    Berg, Kelly A.
    Clarke, William P.
    Woods, James H.
    [J]. FASEB JOURNAL, 2019, 33
  • [4] Long-term Antagonism of <it>Mu</it> Opioid Receptors by Methocinnamox (MCAM) without Adverse Effects on Memory
    Minervini, Vanessa
    France, Charles
    [J]. FASEB JOURNAL, 2020, 34
  • [5] METHOCINNAMOX (MCAM): A NOVEL μ OPIOID RECEPTOR ANTAGONIST FOR TREATING OPIOID USE DISORDER AND OPIOID OVERDOSE
    France, C. P.
    Gerak, L. R.
    Maguire, D. R.
    Javors, M. A.
    Woods, J. H.
    Husbands, S. M.
    Disney, A.
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 43 : 354A - 354A
  • [6] Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox
    Zamora, Joshua C.
    Smith, Hudson R.
    Jennings, Elaine M.
    Chavera, Teresa S.
    Kotipalli, Varun
    Jay, Aleasha
    Husbands, Stephen M.
    Disney, Alex
    Berg, Kelly A.
    Clarke, William P.
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (06):
  • [7] Alvimopan: A peripherally acting mu-opioid receptor antagonist
    Leslie, John B.
    [J]. DRUGS OF TODAY, 2007, 43 (09) : 611 - 625
  • [8] Effects of Methocinnamox, a Long-Acting Mu Opioid Receptor Antagonist, on Fentanyl Choice in Monkeys Responding Under a Food Versus Drug Choice Procedure
    Maguire, David
    France, Charles
    [J]. NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 474 - 474
  • [9] Ligand-Dependent Reversal Kinetics of Mu Opioid Receptor Agonists by the Novel Antagonist, Methocinnamox
    Smith, Hudson R.
    Chavera, Teresa S.
    Berg, Kelly A.
    Clarke, William P.
    [J]. FASEB JOURNAL, 2022, 36
  • [10] Use of a mu-antisense oligodeoxynucleotide as a mu opioid receptor noncompetitive antagonist in vivo
    Chen, XH
    LiuChen, LY
    Tallarida, RJ
    Geller, EB
    deRiel, JK
    Adler, MW
    [J]. NEUROCHEMICAL RESEARCH, 1996, 21 (11) : 1363 - 1368
12345